Chimeric antigen receptor (CAR)-engineered T cell therapy is the most promising approach, which has shown remarkable ability to eliminate various kinds of tumors, especially for B cell malignancies, with up to 95% response rates and durable complete remission. A CAR mainly consists of a single chain variable fragment (scFv) from a monoclonal antibody which binds a specific antigen, a hinge and spacer element, a trans-membrane region and an internal signaling domain such as CD3ζ.
Drug Discovery